SMS Pharmaceuticals Ltd
NSE: SMSPHARMA BSE: 532815Pharma
SMS Pharmaceuticals Ltd is a diversified and integrated pharmaceutical company with interests in Active Pharmaceutical Ingredients (API) and Intermediates.[1]
₹398
52W: ₹208 — ₹448
PE 42.6 · Book ₹81.2 · +390% vs bookMarket Cap₹3,724 Cr
Stock P/E42.6Price to Earnings
ROCE12.2%Return on Capital
ROE11%Return on Equity
Div. Yield0.1%Face Value ₹1
Strengths
- +Company has been maintaining a healthy dividend payout of 24.8%
Weaknesses
- −Stock is trading at 4.88 times its book value
- −Company has a low return on equity of 7.39% over last 3 years.
- −Company might be capitalizing the interest cost
Shareholding Pattern
Promoters68.07%
FIIs0.31%
DIIs3.02%
Public28.6%
| Category | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 64.67% | 64.67% | 64.67% | 66.27%▲1.6 | 66.27% | 68.07%▲1.8 | 68.07% | 68.07% |
| FIIs | 0.18% | 0.52%▲0.3 | 0.31%▼0.2 | 0.08%▼0.2 | 0.03%▼0.1 | 0.28%▲0.3 | 0.04%▼0.2 | 0.31%▲0.3 |
| DIIs | 2.13% | 2.55%▲0.4 | 2.55% | 2.43%▼0.1 | 3.03%▲0.6 | 2.88%▼0.1 | 3.21%▲0.3 | 3.02%▼0.2 |
| Public | 33.03% | 32.27%▼0.8 | 32.47%▲0.2 | 31.23%▼1.2 | 30.68%▼0.6 | 28.77%▼1.9 | 28.69%▼0.1 | 28.6%▼0.1 |
Financial Statements
| Metric | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 167 | 161 | 246 | 164 | 197 | 173 | 248 | 196 | 242 | 210 |
| Expenses | 139 | 133 | 212 | 131 | 165 | 140 | 207 | 157 | 194 | 167 |
| Operating Profit | 28 | 29 | 33 | 33 | 32 | 33 | 41 | 39 | 48 | 44 |
| OPM % | 17% | 18% | 14% | 20% | 16% | 19% | 17% | 20% | 20% | 21% |
| Net Profit | 12 | 12 | 16 | 16 | 14 | 17 | 21 | 18 | 25 | 23 |
| EPS ₹ | 1.42 | 1.44 | 1.88 | 1.93 | 1.68 | 2.03 | 2.33 | 2.05 | 2.68 | 2.49 |
AI Insights
Revenue Trend
TTM revenue at ₹897Cr, up 14.6% YoY. OPM at 19%.
Debt Position
Borrowings at ₹324Cr. Debt-to-equity ratio: 0.43x. Healthy balance sheet.
Capex Cycle
CWIP at ₹50Cr (10% of fixed assets). Moderate ongoing capital expenditure.
Institutional Flow
DIIs: 3.02% (+3.02pp change). FIIs: 0.31% (-0.36pp change). Promoters hold 68.07%.
Margin & Efficiency
ROCE improving from 12% (Mar 2014) to 12% (Mar 2025). Working capital days: 88.
Valuation
PE 42.6x with 12.2% ROCE. Price is 390% above book value of ₹81.2. Dividend yield: 0.1%.
Recent Announcements
- Board Meeting Intimation for Approval Of Financial Results For The Quarter And Financial Year Ended 31St March, 2026 2d - Board meets 22 May 2026 to approve FY26 audited financials and consider dividend; trading window closed until 24 May.
- Announcement under Regulation 30 (LODR)-Monitoring Agency Report 2d - CARE report says SMS Pharmaceuticals fully utilized Rs.114.30 crore warrant proceeds by 31 March 2026, with no deviation.
- Announcement under Regulation 30 (LODR)-Newspaper Publication 2 May - Newspaper Publication regarding " Second 100 days Campaign - Saksham Niveshak
- Confirmation Of Not- Falling Under 'Large Corporate' Criteria 30 Apr - Company confirms it does not fall under Large Corporate criteria as of March 31, 2026.
- Receipt Of Rectification Order By Income Tax Department 29 Apr - Income tax rectification order on 28 Apr 2026 reduced demand to Rs.40.28 lakh from Rs.7.19 crore.
- Financial Year 2025 from bse
- Financial Year 2024 from bse
- Financial Year 2023 from bse